Biopharmaceutical contract manufacturer SK pharmteco commits to production, testing, and release of Ferring’s U.S. approved ADSTILADRIN® ...
GE HealthCare announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), adv...
-DoseMe, a leading provider of model-informed precision dosing (MIPD) software, is pleased to announce the continued growth in Au...
QIAGEN has announced the approval of its NeuMoDx human immunodeficiency virus type 1 (HIV-1) assay for use in Thailand. This approval completes the suite o...
UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024 Anticipated advantages include a new 80 mg mi...
Agilent Technologies Inc. announced that its GenetiSure Dx Postnatal Assay has received European IVDR Class C Certification. This certification demon...
Designed to run seamlessly on the BioCode® MDx-3000 system, this multiplex nucleic acid amplification test delivers unparalleled accuracy in id...
Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-R...
Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its bi...
-OM1, the leading AI and insights-driven technology and data company specializing in personalized medicine, evidence generation, and real-world evidence, t...
GE HealthCare (Nasdaq: GEHC) announces a groundbreaking advancement in cardiac care with the launch of Caption AI artificial intelligence (AI)-driven softw...
EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics, announced th...
Leveraging dsm-firmenich’s high quality GMP CBD active pharmaceutical ingredient (API) and leading-edge formulation capabilities, chiefly its bioavai...
Bristol Myers Squibb (NYSE: BMY) has announced the European Commission's (EC) expanded approval of Reblozyl® (luspatercept) for the first-line ...
© 2025 Biopharma Boardroom. All Rights Reserved.
